Foghorn Therapeutics Inc
$ 4.06
5.45%
11 Jun - close price
- Market Cap 238,379,000 USD
- Current Price $ 4.06
- High / Low $ 4.09 / 3.83
- Stock P/E N/A
- Book Value -1.30
- EPS -1.17
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.21 %
- ROE -4.70 %
- 52 Week High 6.95
- 52 Week Low 3.27
About
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$11.44
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-11 | 2025-11-05 | 2025-08-05 | 2025-05-14 | 2025-03-06 | 2024-11-04 | 2024-08-08 | 2024-05-06 | 2024-03-07 | 2023-11-02 | 2023-08-04 |
| Reported EPS | -0.29 | -0.3654 | -0.25 | -0.28 | -0.3 | -0.3 | -0.31 | -0.45 | -0.59 | -0.57 | -0.34 | -0.7 |
| Estimated EPS | -0.3125 | -0.2589 | -0.3333 | -0.3514 | -0.29 | -0.285 | -0.44 | -0.65 | -0.63 | -0.76 | -0.75 | -0.73 |
| Surprise | 0.0225 | -0.1065 | 0.0833 | 0.0714 | -0.01 | -0.015 | 0.13 | 0.2 | 0.04 | 0.19 | 0.41 | 0.03 |
| Surprise Percentage | 7.2% | -41.1356% | 24.9925% | 20.3187% | -3.4483% | -5.2632% | 29.5455% | 30.7692% | 6.3492% | 25% | 54.6667% | 4.1096% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FHTX
2026-06-06 03:40:10
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company, announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management, including President and CEO Adrian Gottschalk, will present a fireside chat on June 9, 2026, and engage in one-on-one meetings. The company focuses on correcting abnormal gene expression, primarily in oncology, leveraging its Gene Traffic Control® platform.
2026-06-06 03:10:20
Foghorn Therapeutics announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company's President and CEO, Adrian Gottschalk, will present at a fireside chat on June 9, 2026, to discuss Foghorn's Gene Traffic Control® platform and its potential in oncology. A webcast of the fireside chat will be available on the company's website.
2026-06-05 11:09:54
Foghorn Therapeutics Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. Management, including President and CEO Adrian Gottschalk, will present at a fireside chat on June 9, 2026, and engage in one-on-one meetings. The company, a clinical-stage biotechnology firm, focuses on correcting abnormal gene expression, primarily in oncology, leveraging its Gene Traffic Control® platform.
2026-06-05 11:09:22
Foghorn Therapeutics (Nasdaq:FHTX) announced that its management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. President and CEO Adrian Gottschalk will lead a fireside chat on June 9, 2026, at 1:20 p.m. EDT, and engage in one-on-one investor meetings. The clinical-stage biotechnology firm specializes in oncology and abnormal gene expression, utilizing its Gene Traffic Control® platform.
2026-06-05 11:09:22
Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company focused on gene expression correction, announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. The company's President and CEO, Adrian Gottschalk, will present at a fireside chat on Tuesday, June 9, 2026, at 1:20 p.m. EDT, and management will also hold one-on-one meetings. A webcast of the fireside chat will be available on the company's website for 90 days.
2026-05-16 04:09:17
A group of Biotechnology Value Fund (BVF) entities and Mark N. Lampert have disclosed their beneficial ownership in Foghorn Therapeutics Inc. (FHTX) via an amended Schedule 13G filing. As of March 31, 2026, the group holds 3,164,410 shares through BVF, 2,218,382 shares through BVF2, and 6,050,782 pre-funded warrants, although exercise is limited by blockers. The filing details various Series Warrants and clarifies ownership percentages based on 58,700,246 shares outstanding as of February 27, 2026, indicating a collective beneficial ownership of up to 9.99% for some entities due to regulatory limits.
